Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial

Fig. 5

Impact of Denosumab on stromal Tumor Infiltrating Lymphocytes (TILs). A: Percentage of stromal TILs at the diagnostic biopsy (biopsy) and in the surgical specimen (surgery) in the control and experimental arm. p value T test for comparison between experimental and treatment arm is shown in the upper left corner and p value t-test for paired samples is shown for each treatment group. N indicates the number of samples analyzed. B: Representatives images of H&E staining depicting changes in TILs between biopsy and surgery in patients from the control and experimental arm. Black arrows indicate regions with TILs, P denotes the selected patient. Note that only the experimental group exhibited a statistically significant increase in the percentage of TILs

Back to article page